{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:05:47Z","timestamp":1787018747915,"version":"build-2736575974"},"reference-count":36,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Perfusion"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The objective of this study was to describe the implementation and outcomes of a protocol outlining angiotensin-II utilization for vasoplegia following cardiac surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective chart review at a single-center university hospital. Included patients received angiotensin-II for vasoplegia refractory to standard interventions, including norepinephrine 20\u00a0mcg\/min and vasopressin 0.04 units\/min, following cardiac surgery between April 2021 and April 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>30 patients received angiotensin-II for refractory vasoplegia. Adjunctive agents at angiotensin-II initiation included corticosteroids (26 patients; 87%), epinephrine (26 patients; 87%), dobutamine (17 patients; 57%), dopamine (9 patients; 30%), milrinone (2 patients; 7%), and hydroxocobalamin (4 patients; 13%). At 3\u00a0hours, the median mean arterial pressure increased from baseline (70 vs 61.5\u00a0mmHg, p = .0006). Median norepinephrine doses at angiotensin-II initiation, 1\u00a0hour, 3\u00a0hours, and angiotensin-II discontinuation were 0.22, 0.16 ( p = .0023), 0.10 ( p &lt; .0001), and 0.07 ( p &lt; .0001) mcg\/kg\/min. Median dobutamine doses decreased throughout angiotensin-II infusion from eight to six mcg\/kg\/min ( p = .0313). Other vasoactive medication doses were unchanged. Three patients (10%) subsequently received hydroxocobalamin. Thirteen (43.3%) and five (16.7%) patients experienced mortality by day 28 and venous or arterial thrombosis events, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The administration of angiotensin-II to vasoplegic patients following cardiac surgery was associated with increased mean arterial pressure, reduced norepinephrine dosages, and reduced dobutamine dosages.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02676591231215920","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T10:52:11Z","timestamp":1699872731000},"page":"1676-1684","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Angiotensin-II for vasoplegia following cardiac surgery"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0178-1462","authenticated-orcid":false,"given":"Andrew J","family":"Johnson","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tidwell","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McRae","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1357-026X","authenticated-orcid":false,"given":"C Patrick","family":"Henson","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, Division of Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, Division of Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,11,13]]},"reference":[{"key":"bibr1-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.2006.04779.x"},{"key":"bibr2-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1111\/jocs.15663"},{"key":"bibr3-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-2743-8"},{"key":"bibr4-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2017.10.032"},{"key":"bibr5-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(03)01510-8"},{"key":"bibr6-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1007\/s12630-017-1029-3"},{"key":"bibr7-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2020.01.033"},{"key":"bibr8-02676591231215920","volume-title":"Angiotensin II [package insert]","author":"La Jolla Pharmaceutical Company","year":"2020"},{"key":"bibr9-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704154"},{"key":"bibr10-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2020.08.001"},{"key":"bibr11-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000004502"},{"key":"bibr12-02676591231215920","doi-asserted-by":"publisher","DOI":"10.14797\/mdcvj.576"},{"key":"bibr13-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1186\/s13019-021-01665-x"},{"key":"bibr14-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjtc.2020.08.007"},{"key":"bibr15-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2020.07.087"},{"key":"bibr16-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2019.03.004"},{"key":"bibr17-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2018.11.047"},{"issue":"9","key":"bibr18-02676591231215920","doi-asserted-by":"crossref","first-page":"e01266","DOI":"10.1213\/XAA.0000000000001266","volume":"14","author":"Cutler NS","year":"2020","journal-title":"AA Pract"},{"key":"bibr19-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1016\/0888-6296(90)90047-J"},{"key":"bibr20-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1016\/0888-6296(90)90046-I"},{"key":"bibr21-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221099928"},{"key":"bibr22-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1093\/icvts\/ivy352"},{"key":"bibr23-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2021.02.097"},{"key":"bibr24-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202012-4419ED"},{"key":"bibr25-02676591231215920","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v14.i4.250"},{"key":"bibr26-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000005953"},{"key":"bibr27-02676591231215920","volume-title":"Factor IX complex Profilnine\u00ae [package insert]","author":"Grifols Biologicals Inc","year":"2010"},{"key":"bibr28-02676591231215920","volume-title":"KCENTRA (prothrombin complex concentrate (human)) [package insert]","author":"CSL Behring LLC","year":"2023"},{"key":"bibr29-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1186\/s13019-019-0881-3"},{"key":"bibr30-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-018-2225-4"},{"key":"bibr31-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1177\/08850666221145864"},{"key":"bibr32-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2003.11.032"},{"key":"bibr33-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2013.02.026"},{"key":"bibr34-02676591231215920","volume-title":"Inc. Methylene Blue [package insert]","author":"American Regent","year":"2021"},{"key":"bibr35-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1080\/15563650701829763"},{"key":"bibr36-02676591231215920","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2706-0"}],"container-title":["Perfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02676591231215920","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02676591231215920","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02676591231215920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:33:53Z","timestamp":1777656833000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02676591231215920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1177\/02676591231215920"],"URL":"https:\/\/doi.org\/10.1177\/02676591231215920","relation":{},"ISSN":["0267-6591","1477-111X"],"issn-type":[{"value":"0267-6591","type":"print"},{"value":"1477-111X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,13]]}}}